Yazar "Dincer, Mevlut Tamer" seçeneğine göre listele
Listeleniyor 1 - 5 / 5
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe A comparison of antibody response in kidney transplant recipients and healthcare workers who had PCR-confirmed COVID-19 infection(Tubitak Scientific & Technological Research Council Turkey, 2022) Dincer, Mevlut Tamer; Eren, Necmi; Murt, Ahmet; Yildiz, Nuriye; Ozcan, Seyda Gul; Ergul, Metin; Bek, Sibel GokcayBackground/aim: Data on antibody response following COVID-19 in kidney transplant recipients is scarce. This crosssectional study aims to investigate the antibody response to COVID-19 among kidney transplant recipients. Materials and methods: We recruited 46 kidney transplant recipients with RT-PCR-confirmed COVID-19 and 45 recipients without COVID-19 history. We also constructed two control groups (COVID-19 positive and negative) from a historical cohort of healthcare workers. We used age and sex-based propensity score matching to select the eligible subjects to the control groups. We measured the SARS-CoV-2 IgG levels quantitatively using the Abbott ARCHITECT system. An antibody level above 1.4 S/C was defined as positivity. Results: Transplant recipients with COVID-19 had a higher BMI, and COVID-19 history in a household member was more common than that of the transplant recipient without COVID-19. IgG seropositivity rate (69.6% vs. 78.3%, p = 0.238) and the median IgG level (3.28 [IQR: 0.80-5.85] vs. 4.59 [IQR: 1.61-6.06], p = 0.499) were similar in COVID-19-positive transplant recipients and controls. Kidney transplant recipients who had a longer duration between RT-PCR and antibody testing had lower antibody levels (r = -0.532, p < 0.001). Conclusion: At the early post-COVID-19 period, kidney transplant recipients have a similar antibody response to controls. However, these patients' antibody levels and immunity should be closely monitored in the long term.Öğe ASSOCIATION OF MULTIPLE PLASMA BIOMARKER LEVELS WITH KIDNEY DISEASE ACTIVITY IN FABRY DISEASE(Oxford Univ Press, 2023) Ozcan, Seyda Gul; Atli, Zeynep; Eren, Necmi; Dincer, Mevlut Tamer; Turkmen, Kultigin; Ozer, Hakan; Trabulus, Sinan[No abstract available]Öğe Comparative Analysis of ChatGPT and Gemini in Addressing Questions from Chronic Kidney Disease Patients(Mdpi, 2026) Bati Sutcu, Yasemin; Ozcan, Seyda Gul; Dincer, Mevlut Tamer; Atli, Zeynep; Trabulus, Sinan; Seyahi, NurhanBackground: Chronic kidney disease (CKD) is a major global health burden. Patient education is a crucial part of CKD management. Large language models (LLMs) such as ChatGPT and Gemini may help patients access medical information, but their reliability in CKD-related contexts is uncertain. Methods: We collected 291 questions from 100 CKD patients and selected and analyzed 123 of them across three categories: medical condition and treatment, nutrition and diet, and symptom management. Responses from ChatGPT and Gemini were assessed by two nephrology specialists using the Quality Assessment of Medical Artificial Intelligence (QAMAI) scale. Results: When all 123 questions were evaluated together, ChatGPT outperformed Gemini in terms of clarity and usefulness. However, when the questions were analyzed by category, Gemini demonstrated relatively stronger performance in the nutrition and symptom management domains. Accuracy and relevance were comparable between the two models. Neither consistently provided adequate citations. Conclusion: ChatGPT and Gemini demonstrate potential as supplementary tools for CKD patient education, with complementary strengths across different domains. Although they cannot replace clinical expertise, their supervised use could enhance information access and reduce clinician burden.Öğe Effects of Antithymocyte Globulin, Basiliximab, and Induction-Free Treatment in Living Donor Kidney Transplant Recipients on Tacrolimus-Based Immunosuppression(Baskent Univ, 2024) Sonmez, Ozge; Ozcan, Seyda Gul; Karaca, Cebrail; Atli, Zeynep; Dincer, Mevlut Tamer; Trabulus, Sinan; Seyahi, NurhanObjectives: Induction treatment in renal transplant is associated with better graft survival. However, intensified immunosuppression is known to cause unwanted side effects such as infection and malignancy. Furthermore, the effects of the routine use of immunosuppressants in low -risk kidney transplant recipients are still not clear. In this study, we assessed the first -year safety and efficacy of induction treatment. Materials and Methods: We examined first living donor kidney transplant patients who were on tacrolimusbased immunosuppression therapy. We formed 3 groups according to the induction status: antithymocyte globulin induction, basiliximab induction, and no induction. We collected outcome data on delayed graft function, graft loss, creatinine levels, estimated glomerular filtration rates, acute rejection episodes, hospitalization episodes, and infection episodes, including cytomegalovirus infection and bacterial infections. Results: We examined a total of 126 patients (age 35 +/- 12 years; 65% male). Of them, 25 received antithymocyte globulin, 52 received basiliximab, and 49 did not receive any induction treatment. We did not observe any statistically significant difference among the 3 groups in terms of acute rejection episodes, delayed graft function, and first -year graft loss. The estimated glomerular filtration rates were similar among the groups. Overall bacterial infectious complications and cytomegalovirus infection showed similar prevalence among all groups. Hospitalization was less common in the induction -free group. Conclusions: In low -risk patients, induction -free regimens could be associated with a better safety profile without compromising graft survival. Therefore, induction treatment may be disregarded in first living donor transplant patients who receive tacrolimusbased triple immunosuppression treatment.Öğe The relationship between multiple plasma biomarker levels and renal disease activity in Fabry disease(Bmc, 2025) Ozcan, Seyda Gul; Eren, Necmi; Dincer, Mevlut Tamer; Atli, Zeynep; Bolayirli, Murat; Ergul, Metin; Ozer, HakanBackground Fabry disease is a rare lysosomal storage disorder. The genotypic and phenotypic heterogeneity of the disease complicates the prediction of disease activity. This study aimed to evaluate the association between multiple plasma biomarkers and disease activity in Fabry disease. Methods A cross-sectional analysis was conducted involving 87 Fabry patients, 46 chronic kidney disease (CKD) patients, and 41 healthy controls. Plasma levels of KIM-1, MCP-1, YKL-40, TNFR-1, TNFR-2, and cystatin-C were measured using ELISA. eGFR was calculated using creatinine and creatinine-cystatin C-based CKD-EPI formulas. Fabry patients on renal replacement therapy were analyzed as a subgroup. Primary analyses focused on 62 Fabry patients receiving enzyme replacement therapy. Results Although eGFR (cr) did not differ significantly between Fabry patients and healthy controls, eGFR(cr-cys) was significantly lower in Fabry patients. After adjusting for age, gender, and BMI, MCP-1 and TNFR-2 levels were significantly lower in Fabry patients than in CKD patients. Among Fabry patients, those with renal involvement, had significantly higher MCP-1 levels than those without. While KIM-1 and YKL-40 did not differ significantly between groups, both were significantly elevated in patients with Lyso-Gb3 > 4 ng/mL and positively correlated with Lyso-Gb3. Conclusion MCP-1, TNFR-2, YKL-40, and cystatin C may serve as potential biomarkers for different aspects of Fabry disease activity. Further investigation into the associated pathogenic pathways may support the development of novel diagnostic tools or targeted therapies.
